Cellyan Biotechnology Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 4, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Market Cap	12	12	-	-
Market Cap Growth	-13.10%	-	-	-
Enterprise Value	12.01	10.38	0	0
Last Close Price	0.52	1.08	-	-
PS Ratio	0.75	0.58	-	-
PB Ratio	1.11	2.38	-	-
P/TBV Ratio	1.09	2.21	-	-
P/FCF Ratio	-	23.79	-	-
P/OCF Ratio	-	20.87	-	-
EV/Sales Ratio	0.73	0.51	-	-
EV/EBITDA Ratio	-	8.62	-	-
EV/EBIT Ratio	-	78.65	-	-
EV/FCF Ratio	-	20.80	-	-
Debt / Equity Ratio	0.28	0.30	0.30	0.46
Debt / EBITDA Ratio	5.28	1.97	0.82	0.39
Debt / FCF Ratio	-	4.76	-	0.43
Net Debt / Equity Ratio	-0.04	-0.13	0.35	0.28
Net Debt / EBITDA Ratio	-0.48	-0.52	0.58	0.10
Net Debt / FCF Ratio	0.42	-1.26	-3.28	0.10
Asset Turnover	1.72	2.25	2.76	3.69
Inventory Turnover	25.87	23.97	23.36	51.43
Quick Ratio	2.73	2.80	1.76	1.00
Current Ratio	2.93	2.99	2.46	1.08
Return on Equity (ROE)	-13.85%	-0.59%	54.96%	170.56%
Return on Assets (ROA)	-6.31%	-1.09%	23.21%	29.96%
Return on Invested Capital (ROIC)	-12.09%	-1.90%	38.62%	75.84%
Return on Capital Employed (ROCE)	-10.08%	2.20%	50.67%	121.84%
FCF Yield	-	4.20%	-	-
Buyback Yield / Dilution	-19.69%	-38.56%	-7.64%	-
Total Shareholder Return	-19.69%	-38.56%	-7.64%	-

SEC Filings: 10-K · 10-Q